Tandem triplicate A29L peptide elicits robust immune responses against monkeypox virus in mice Authors: Chia-Yu Liang, Ting-Yu Chang, Pei-Hsuan Chen, Tai-Ling Chao, Sui-Yuan Chang, Shih-Chung Chang Published: 2026 ABSTRACT AbstractAbstractMonkeypox (Mpox) remains a significant public health concern due to the emergence of rapidly evolving strains and the suboptimal efficacy of existing smallpox vaccines. Recombinant subunit vaccines offer a promising and safe alternative. The A29L protein of the Mpox virus (MPXV) is essential for viral attachment and entry. The N-terminal residues 1–34 of A29L, which harbor the heparin-binding domain, are critical targets for neutralizing antibodies. Based on this, we hypothesized that this truncated 34-residue peptide of A29L could serve as a potent subunit vaccine candidate. To enhance immunogenicity, the recombinant antigen comprising three tandem repeats of the 34-residue peptide (designated as Tri(1–34)) was engineered. Following the immunization of BALB/c mice, Tri(1–34) elicited robust A29L-specific antibody titers comparable to those induced by the full-length protein, demonstrating equivalent immunogenicity. Furthermore, antisera collected from Tri(1–34)-immunized mice specifically recognized the A29L N-terminus and effectively neutralized MPXV infection in Vero E6 cells, as evidenced by the plaque reduction neutralization test (PRNT) assays. Immunization with Tri(1–34) also triggered strong Th1-biased cellular immune responses, characterized by significant interferon-gamma (IFN-γ) production. In conclusion, the engineered Tri(1–34) antigen represents a safe and effective subunit vaccine candidate, offering a strategic framework for future Mpox vaccine development.Key points• Engineered Tri(1–34) targets the critical A29L N-terminus of Mpox virus• Tri(1–34) elicits potent neutralizing antibodies against Mpox virus• Tri(1–34) induces a robust Th1-biased response with high IFN-γ levelsSupplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00253-026-13936-5.Keywords: Monkeypox virus (MPXV), A29L protein, Subunit vaccine, Humoral immunity, Cellular immunity, Neutralizing antibody Introduction Monkeypox (Mpox), caused by the monkeypox virus (MPXV), has emerged as the foremost orthopoxvirus threat in the post-smallpox era (Gong et al. 2022). Recent global outbreaks have seen the virus traverse geographical boundaries into previously non-endemic territories at an alarming pace (Haque et al. 2024; Rizk et al. 2024). This resurgence is largely fueled by the evolution of MPXV lineages that possess accelerated mutation rates and optimized human-to-human transmission dynamics (Isidro et al. 2022; Otieno et al. 2024; Zhu et al. 2023). Given that severe manifestations can be fatal, MPXV represents a formidable challenge to international health security (Vasudevan et al. 2025). While smallpox vaccination provides approximately 85–87% cross-protective efficacy against MPXV (Christodoulidou and Mabbott 2023), the ongoing genetic drift of the virus may enable it to bypass established immune barriers and potentially diminish the efficacy of traditional smallpox vaccines against new strains (Huang et al. 2022; Wang et al. 2023). Furthermore, population-wide immunity is waning; younger generations largely remain immunologically naive, while older individuals experience a natural decline in vaccine-induced antibody longevity (Byrne et al. 2025). Given the genetic similarities between MPXV and vaccinia virus (VACV) (Shchelkunov et al. 2001), a non-replicating modified vaccinia Ankara (MVA)-based vaccine JYNNEOS (also known as IMVAMUNE, IMVANEX, or MVA-Bavarian Nordic (MVA-BN)) currently serves as the primary preventative measure for Mpox (Desai and Malani 2023; Jiang et al. 2025). However, evidence suggests that the two-dose JYNNEOS vaccination generates relatively low levels of MPXV-neutralizing antibodies in healthy individuals (Zaeck et al. 2023). Furthermore, its effectiveness is modest, with full JYNNEOS vaccination offering only 66.0% protection and single-dose regimens falling as low as 35.8% (Deputy et al. 2023; Ghazy et al. 2023; Taha et al. 2024). Reports of breakthrough infections and safety concerns ranging from severe dermatological issues to rare cardiac complications like myocarditis (Rizk et al. 2022; Sudarmaji et al. 2022) highlight the necessity for next-generation recombinant subunit vaccines, which offer superior safety profiles and targeted immunogenicity. The MPXV A29L protein is an essential surface antigen involved in viral docking and entry into host cells (Chung et al. 1998; Shi et al. 2022) and is identified as a critical surface target for neutralizing antibodies (Gilchuk et al. 2016; Moss 2011; Tang et al. 2023). As a functional homolog of the VACV A27L protein, A29L utilizes its N-terminal heparin-binding domain (HBD, residues 21–32) to facilitate infection (Hsiao et al. 1998; Shi et al. 2022). Consequently, shielding this region with antibodies can effectively neutralize the virus. Previous studies have identified potent monoclonal antibodies, such as 12C3 (Kaever et al. 2016) and 9F8 (Li et al. 2023b), that target linear epitopes within the A29L N-terminus. These antibodies demonstrate robust cross-neutralizing activity, suggesting that the initial 34 residues of A29L hold significant promise as a vaccine subunit. A subset of VACV- and MPXV-neutralizing antibodies also target the HBD or adjacent regions (Kaever et al. 2016; Li et al. 2023b; Riccardo and Pablo 2023). Based on these insights, we hypothesized that the N-terminal 34 residues of A29L could serve as a potent subunit vaccine candidate. To amplify this effect, the antigen named Tri(1–34) comprising three tandem repeats of this 34-residue peptide was engineered. To optimize protein folding and solubility within mammalian expression systems, we further fused this construct with a human Fc fragment via a flexible GGGGS linker (Li et al. 2023a) to create the Tri(1–34)-hFc antigen. We conducted a comparative immunogenicity study in BALB/c mice using full-length A29L, Tri(1–34), and Tri(1–34)-hFc formulated with Freund’s adjuvant. Following a three-dose priming-boosting schedule, specific IgG titers were quantified by enzyme-linked immunosorbent assay (ELISA), and neutralizing capabilities were verified by plaque reduction neutralization test (PRNT) assays. Additionally, cellular immunity was scrutinized by analyzing interferon-gamma (IFN-g) and interleukin-4 (IL-4) from stimulated splenocytes to determine the overall depth of the induced immune response. Materials and methods Preparation of recombinant A29L and Tri(1–34) antigens The Tri(1–34) construct was engineered by tandemly linking three copies of the N-terminal 34 amino acids of the MPXV A29L protein using flexible GGGGS spacers (Fig. 1a). Synthetic genes for both wild-type A29L (GenBank: AAQ72865.1) and the Tri(1–34) variant (Synbio Technologies, Monmouth Junction, NJ, USA), each featuring a C-terminal 6 × His-tag, were cloned into pET28a vectors (Merck Millipore, Burlington, MA, USA). The Escherichia coli BL21(DE3) strain (Merck Millipore, Burlington, MA, USA) was utilized for A29L expression, while the E. coli Rosetta(DE3) strain (Merck Millipore, Burlington, MA, USA) was employed for Tri(1–34). Cultures were grown in the Luria–Bertani (LB) medium (Thermo Fisher Scientific, Waltham, MA USA) containing appropriate antibiotics (100 μg/mL kanamycin and/or 34 μg/mL chloramphenicol) until reaching an OD600 of 0.4–0.6. A29L production was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 18 °C for 16 h. In contrast, Tri(1–34) expression was induced with 1 mM IPTG at 37 °C for 4 h. Following cell homogenization in lysis buffer (20 mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole; pH 7.4), proteins were captured using HisTrap HP columns (Cytiva, Marlborough, MA, USA) and eluted using a 25–500 mM imidazole gradient. A29L was further purified using a HiTrap Heparin HP column (Cytiva, Marlborough, MA, USA) with a linear NaCl gradient (0–1.5 M, pH 7.0), whereas Tri(1–34) underwent size-exclusion chromatography using a HiLoad 16/600 Superdex 75 pg column (Cytiva, Marlborough, MA, USA). Final samples were desalted into phosphate-buffered saline (PBS), sterilized via 0.22-μm filtration, and kept at 4 °C until use. Immunization with A29L and Tri(1–34) elicited humoral immune responses. a Schematic representation of the recombinant Tri(1–34) antigen constructed with three tandem repeats of the N-terminal 34 residues of A29L (underlined and bolded), separated by GGGGS linkers. The sequence includes a leucine (L) and a glutamate (E) residue encoded by the XhoI restriction site, followed by a C-terminal 6 × His tag (HHHHHH). b A29L and Tri(1–34) were expressed in E. coli. Tri(1–34)-hFc was expressed in the Expi293 cells. Purified proteins were analyzed using SDS-PAGE and Coomassie staining. c Experimental design and immunization schedule. d Mouse body weights were measured every seven days following the start of the immunization process. e The survival percentage of mice in each group was recorded throughout the duration of the experiment. f A29L-specific IgG titers were measured by ELISA using mouse sera collected after each immunization. PBS group, gray bars; A29L group, orange bars; Tri(1–34) group, green bars; Tri(1–34)-hFc group, blue bars. Data are presented as mean ± standard deviation (SD) from three independent experiments. Additionally, the exact values of all serum samples were displayed in all bar graphs (PBS group, gray triangles; A29L group, orange diamonds; Tri(1–34) group, green circles; Tri(1–34)-hFc group, blue squares). Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Preparation of recombinant Tri(1–34)-hFc antigen A chimeric gene consisting of an N-terminal secretory signal peptide (METGLRWLLLVAVLKGVQC), the Tri(1–34) sequence, and a human IgG Fc domain (GenBank: AEV43323.1) connected via a GGGGS linker was integrated into a pTT5 expression vector (Addgene, Watertown, MA, USA). Expi293F cells (Thermo Fisher Scientific, Waltham, MA, USA) were transiently transfected with the pTT5-Tri(1–34)-hFc plasmid using ExpiFectamine 293 reagents (Thermo Fisher Scientific, Waltham, MA, USA). After 5 days of cultivation (37 °C, 8% CO2), the supernatant was harvested. The fusion protein was isolated using HisTrap FF column (Cytiva, Marlborough, MA, USA) with a 25–500 mM imidazole gradient, followed by purification on a HiTrap Protein A HP column (Cytiva, Marlborough, MA, USA). The protein was eluted with 0.1 M sodium citrate (pH 3.0), neutralized into PBS, and stored at 4 °C until use. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie staining Protein samples were resolved by SDS-PAGE under reducing conditions using a discontinuous buffer system. All solutions were prepared with deionized water (ddH2O). The electrophoresis running buffer consisted of 25 mM Tris base, 192 mM glycine, and 0.1% (w/v) SDS, with a final pH of approximately 8.3. The 4 × reducing sample buffer was formulated to contain 500 mM Tris–HCl (pH 6.8), 8% (w/v) SDS, 40% (v/v) glycerol, 0.04% (w/v) bromophenol blue, and 20% (v/v) b-mercaptoethanol. The bottom resolving gel was prepared by mixing a 30% acrylamide/bis-acrylamide solution (29:1), 1.5 M Tris–HCl (pH 8.8), and 10% (w/v) SDS. Gel polymerization was initiated by the addition of 0.05% (w/v) ammonium persulfate (APS) and 0.09% (v/v) N,N,N′,N′-tetramethyl-ethylenediamine (TEMED). The mixture was immediately poured into the glass plate cassette, overlaid with isopropanol, and allowed to polymerize at room temperature for 30 min. Following removal of the top overlay and rinsing with ddH2O, a 4% stacking gel solution containing 0.5 M Tris–HCl (pH 6.8), SDS, APS, and TEMED was cast on top of the resolving gel, and a Teflon comb was inserted. The stacking gel was allowed to polymerize for an additional 20 min. For sample preparation, protein samples were mixed with the reducing sample buffer and then incubated in a thermal block at 100 °C for 10 min. After assembling the gel cassette into the electrophoresis tank and filling the chambers with running buffer, the denatured protein samples and a pre-stained protein molecular weight marker were loaded into the designated wells. Electrophoresis was performed at a constant voltage of 170 V and terminated when the bromophenol blue tracking dye reached the bottom edge of the gel. For performing the Coomassie staining, the resulting gel was stained with 0.15% (w/v) Coomassie Brilliant Blue R-250 in 10% acetic acid and 20% methanol solution at room temperature for 15 min with shaking, and subsequently destained with 10% acetic acid and 20% methanol solution until appearing a clear gel background. Mouse immunization Seven-week-old male BALB/c mice (National Laboratory Animal Center, Taipei City, Taiwan) were randomly assigned to groups (n = 3 for PBS control; n = 5 for A29L, Tri(1–34), or Tri(1–34)-hFc groups). Immunizations were administered intraperitoneally on days 0, 14, and 28. Each animal received PBS or 50 μg of either A29L, Tri(1–34), or Tri(1–34)-hFc emulsified in 100 μL Freund’s adjuvant (EMD Millipore Corporation, Burlington, MA, USA). Serum samples were obtained via submandibular bleeding 7 days after each dose. To prepare the antisera, samples were heat-inactivated at 56 °C for 30 min, clarified by centrifugation, and filtered (0.22 μm) before being frozen at − 20 °C. Determination of antigen-specific IgG titers by ELISA To quantify antibody titers, 96-well plates were coated with 100 ng of purified A29L at 37 °C for 1 h. Following a blocking step with 5% non-fat milk for 1 h, serial dilutions of mouse sera in 0.25% gelatin-PBST (PBS with 0.05% Tween-20) were incubated in the wells for 1 h. After washing with PBST, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody (SeraCare, Milford, MA, USA) (1:50,000) was applied in the wells for 1 h of incubation. Colorimetric development was initiated using a substrate solution containing hydrogen peroxide and 3,3′,5,5′-tetramethylbenzidine (TMB) (Hong Da Life Sciences, Taipei City, Taiwan) and halted to measure absorbance at 450 nm. Western blot (WB) Proteins were separated on SDS-PAGE under the reducing condition and transferred onto a polyvinylidene difluoride (PVDF) membrane (EMD Millipore Corporation, Burlington, MA, USA). The transferred PVDF membrane was blocked with 5% non-fat milk prepared in PBST at room temperature with continuous shaking for 1 h. After blocking, the membrane was washed three times with PBST for 10 min each. Subsequently, the membrane was incubated with anti-His mAb diluted 1:5000 or mouse serum diluted 1:2000 in 0.25% gelatin-PBST at room temperature for 1 h with shaking. To remove unbound primary antibodies, the membrane was washed three times with PBST for 10 min per wash. The membrane was then incubated with HRP-conjugated goat anti-mouse IgG secondary antibody (SeraCare, Milford, MA, USA) diluted 1:2000 in 0.25% gelatin-PBST at room temperature with shaking for 1 h, followed by another three washes with PBST. Finally, the PBST was removed, and the membrane was incubated with the chemiluminescent substrate (Cytiva, Marlborough, MA, USA). The WB signal was captured by the UVP BioSpectrum Imaging System (Upland, CA, USA). PRNT assay Vero E6 cells isolated from the kidney of an African green monkey with epithelial morphology (ATCC CRL-1586, Manassas, VA, USA) were prepared in 24-well plates (2 × 105 cells/well) 24 h prior to the assay (Liang et al. 2024). Mouse antisera (5 μL) were pre-incubated with 50 plaque-forming unit (PFU) of MPXV (200 μL) for 1 h at 37 °C before being added to the cell monolayers. After a 1-h infection period, the mixture was replaced with an overlay medium. Following a 7-day incubation, cells were fixed with 10% formalin and visualized with 0.5% crystal violet. Evaluation of T-cell immune responses Three weeks post the final vaccination, splenocytes were harvested and maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA USA) at 37 °C in a 5% CO2 incubator. A total of 5 × 105 cells/well were stimulated with 50 μg/mL of recombinant A29L for 72 h. The concentrations of IFN-γ and IL-4 in the culture supernatants were determined using ELISA MAX Deluxe kits (BioLegend, San Diego, CA, USA) according to the manufacturer’s instructions. Data were obtained from three independent experiments. Statistical analysis Data were analyzed using GraphPad Prism 10 (GraphPad Software, Boston, MA, USA) and are presented as mean ± standard deviation (SD). Statistical significance was determined using one-way ANOVA followed by Tukey’s or Dunnett’s multiple comparisons tests. P-values are represented as follows: ****P ≤ 0.0001, ***P < 0.001, **P < 0.01, and *P ≤ 0.05. Results Humoral immune responses induced by Tri(1–34) immunization To evaluate the immunogenicity of the engineered antigens, the purified recombinant full-length A29L, Tri(1–34), and Tri(1–34)-hFc (Fig. 1b and Supplementary Fig. S1) were formulated with Freund’s adjuvant and administered to BALB/c mice in a three-dose immunization protocol at 2-week intervals (Fig. 1c). The safety of the recombinant A29L, Tri(1–34), and Tri(1–34)-hFc antigens was monitored by measuring body weight and survival rates over a 35-day period. Mice in both PBS and the antigen-immunized groups exhibited a steady and comparable increase in body weight (Fig. 1d), with no significant differences or signs of toxicity observed. Additionally, the survival rate remained at 100% for all experimental groups throughout the entire observation period (Fig. 1e). These results indicate that the recombinant A29L, Tri(1–34), and Tri(1–34)-hFc antigens are safe and well-tolerated in vivo. Antisera were collected prior to immunization and 2 weeks after each dose (Fig. 1c) to measure A29L-specific antibody titers by ELISA. The results demonstrated that the A29L-specific antibody titers were significantly elevated 1 week after the second dose (day 21) in mice immunized with A29L, Tri(1–34), or Tri(1–34)-hFc compared to the PBS control group (Fig. 1f). Titers reached their peak one week after the third dose (day 35; Fig. 1f). Notably, Tri(1–34) and Tri(1–34)-hFc elicited antibody levels comparable to those induced by the full-length A29L protein, suggesting that the immunogenicity of the Tri(1–34) antigen is equivalent to that of the full-length A29L. Characterization of the antibody profile induced by Tri(1–34) To determine whether immunization with Tri(1–34) and Tri(1–34)-hFc specifically elicits antibodies against the N-terminal region of A29L, western blot (WB) analysis was performed using the antisera collected on day 35 (Fig. 1c). The full-length A29L and two truncated fragments comprising residues 2–41 and 42–110 (Liang et al. 2024) (Fig. 2a and Supplementary Fig. S2) were used as antigens. Antisera from A29L-immunized mice recognized A29L(2–41), A29L(42–110), and the full-length protein (Fig. 2b); however, the signals for A29L(2–41) (Fig. 2b, lane 1) were weaker than those for A29L(42–110) (Fig. 2b, lane 2). In contrast, antisera from mice immunized with Tri(1–34) or Tri(1–34)-hFc exclusively recognized A29L(2–41) and the full-length protein (Fig. 2c and d, lanes 1 and 3). These findings indicate that immunization with Tri(1–34) specifically stimulates the production of antibodies targeting the N-terminal portion of A29L. Induction of specific antibodies against the A29L N-terminus by Tri(1–34). a Recombinant fragments A29L(2–41) (lane 1), A29L(42–110) (lane 2), and full-length A29L(2–110) (lane 3) in conjugation with superfolder green fluorescent protein (sfGFP) were analyzed by SDS-PAGE and Coomassie staining (left panel). WB analysis was performed using an anti-His mAb (right panel) as a control antibody to detect these three fragments. To characterize the antibody profiles induced by A29L and Tri(1–34), WB analysis was performed using antisera collected on day 42 (Fig. 1c) from five individual mice (#1–5) which were immunized with A29L (b), Tri(1–34) (c), or Tri(1–34)-hFc (d) Induction of MPXV neutralizing antibodies by Tri(1–34) To determine whether the antibodies elicited by the engineered antigens possess functional neutralizing activity, PRNT assays were conducted using Vero E6 cells. Antisera collected from mice immunized with PBS, full-length A29L, Tri(1–34), or Tri(1–34)-hFc (day 42) were incubated with MPXV prior to cell infection. The results showed that the virus and PBS control groups exhibited a high number of viral plaques (Fig. 3a), indicating a lack of an inhibitory effect. In contrast, treatment with antisera from mice immunized with A29L, Tri(1–34), or Tri(1–34)-hFc resulted in a visible reduction in the number of plaques across multiple biological replicates (Fig. 3a). Quantitative analysis (Fig. 3b) revealed that the inhibition rates for the A29L, Tri(1–34), and Tri(1–34)-hFc groups were significantly higher than that of the PBS control group (****P < 0.0001). Specifically, the Tri(1–34) and Tri(1–34)-hFc antigens achieved mean inhibition rates of approximately 67.7% and 64.1%, respectively, which were comparable to the 66.3% inhibition observed in the full-length A29L group. These results demonstrate that the engineered Tri(1–34) antigen can effectively elicit potent neutralizing antibodies that block MPXV infection, confirming that the N-terminal residues 1–34 are a critical target for protective immunity. Elicitation of MPXV neutralizing antibodies by Tri(1–34). a PRNT results using antisera (1:40 dilution) from mice immunized with PBS (n = 3), A29L (n = 5), Tri(1–34) (n = 5), or Tri(1–34)-hFc (n = 5). Representative images from three independent assays were shown. Cell: Vero E6 cells; Virus: Vero E6 cells infected with 50 PFU of MPXV. b Quantitative analysis of neutralization efficacy. The percentage of inhibition was calculated by comparing plaque counts in the presence of serum to the virus-only control. Data are presented as mean ± SD. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparisons test. ****P < 0.0001 Adaptive cellular immunity elicited by Tri(1–34) To evaluate the adaptive cellular immune responses induced by the various vaccine candidates, splenocytes from immunized BALB/c mice were harvested and stimulated with purified A29L protein in vitro. The secretion levels of IFN-γ (a marker for Th1 responses) and IL-4 (a marker for Th2 responses) were quantified using ELISA. As shown in Fig. 4a, stimulation with A29L antigen significantly increased IFN-γ production in splenocytes from A29L- and Tri(1–34)-immunized mice compared to the PBS control group. Remarkably, the Tri(1–34) group exhibited a robust Th1-biased response, with IFN-γ levels reaching approximately 4700 pg/mL, which was significantly higher than that observed in the full-length A29L group (approx. 1000 pg/mL; ****P < 0.0001) and the Tri(1–34)-hFc group (****P < 0.0001). Regarding the Th2-biased response (Fig. 4b), the full-length A29L group showed the highest induction of IL-4 (approx. 22 pg/mL) compared to all other groups (****P < 0.0001). In contrast, while Tri(1–34) elicited a slight increase in IL-4 compared to the PBS control, its primary effect was the induction of a potent IFN-γ response. Interestingly, the Tri(1–34)-hFc group showed minimal cellular immune activation for both cytokines under the tested conditions. These results suggest that while the full-length A29L induces a balanced Th1/Th2 cellular response, the engineered Tri(1–34) antigen is a potent inducer of Th1-mediated cellular immunity, characterized by high levels of IFN-γ secretion, which may play a critical role in the clearance of MPXV infection. Induction of cellular immune responses by Tri(1–34). Splenocytes isolated from mice immunized with three doses of PBS, A29L, Tri(1–34), or Tri(1–34)-hFc were cultured and stimulated with purified A29L protein. After 72 h, culture supernatants were analyzed for IFN-g (a) and IL-4 (b) concentrations by ELISA. Data are presented as mean ± SD from three independent experiments. Statistical significance was calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05; ****P < 0.0001 Discussion The global resurgence of Mpox has underscored the limitations of current vaccination strategies, particularly the suboptimal efficacy and safety concerns associated with live-attenuated smallpox vaccines like JYNNEOS. In this study, we demonstrated that the engineered subunit vaccine candidate, Tri(1–34), derived from the HBD of the MPXV A29L protein, elicits robust humoral and cellular immune responses in mice, offering a promising and safer alternative for Mpox prevention. Our results confirm the hypothesis that the N-terminal residues 1–34 of A29L are sufficient to induce potent neutralizing antibodies. While the full-length A29L contains multiple epitopes, WB analysis (Fig. 2) revealed that antisera from A29L-immunized mice predominantly targeted the C-terminal portion (residues 42–110), with relatively weaker reactivity toward the N-terminus. However, the N-terminal HBD is functionally critical for viral attachment to host heparan sulfate (Hsiao et al. 1998; Shi et al. 2022). By engineering Tri(1–34)—three tandem repeats of this domain—we effectively shifted the immune focus toward this vulnerable site. Tri(1–34) robustly induced A29L-specific antibody titers that were comparable to those elicited by the full-length A29L protein (Fig. 1f), indicating similar immunogenicity. WB analysis further confirmed that the antibodies induced by Tri(1–34) specifically recognized the N-terminal portion of A29L (Fig. 2c), reinforcing the precision of our vaccine design. The PRNT assays (Fig. 3) further validated this strategy, showing that Tri(1–34)-induced antibodies neutralized MPXV with an efficiency comparable to those induced by the full-length protein (~ 67% inhibition). This suggests that the N-terminal 1–34 region is not only a viable target but perhaps a more efficient one for rational vaccine design. Subunit vaccines often face challenges regarding low immunogenicity (Cheng et al. 2025). To overcome this, we employed a tandem repeat strategy. The comparable IgG titers between Tri(1–34) and full-length A29L (Fig. 1f) indicate that the repetitive display of the N-terminal 34-residue peptide effectively mimics the multivalent nature of viral surfaces, enhancing B-cell receptor signaling and subsequent antibody production. Interestingly, while the Tri(1–34)-hFc fusion protein was designed to improve solubility and potentially enhance half-life via the Fc fragment (Bai et al. 2025), it did not significantly outperform the non-Fc version in terms of neutralization or cellular immunity. This is possibly due to the large Fc domain partially masking certain conformational epitopes or altering antigen processing by antigen-presenting cells. A standout finding in our study was the exceptionally high level of IFN-γ induced by Tri(1–34) (Fig. 4a). In viral infections, a Th1-biased response characterized by IFN-γ production is crucial for activating cytotoxic T lymphocytes and macrophages to clear virus-infected cells (Yang et al. 2023). The fact that Tri(1–34) elicited nearly a fivefold increase in IFN-γ compared to the full-length A29L protein suggests that this truncated antigen may contain a highly potent T-cell epitope that becomes more accessible to major histocompatibility complex (MHC) molecules when removed from the context of the full-length protein. Conversely, the full-length A29L induced higher IL-4 levels (Fig. 4b), suggesting a more balanced Th1/Th2 response. Given that cellular immunity is vital for long-term protection against orthopoxviruses (Zhang et al. 2023), the strong Th1 signature of Tri(1–34) is a significant advantage. Beyond immunogenicity, we also evaluated the in vivo safety of the recombinant antigens. Over a 35-day observation period, mice immunized with A29L, Tri(1–34), or Tri(1–34)-hFc exhibited steady body weight gain comparable to the PBS control group, with no observable signs of toxicity or distress (Fig. 1d). Furthermore, a 100% survival rate was maintained across all experimental groups (Fig. 1e), indicating that these subunit vaccine candidates are safe and well-tolerated. However, a notable limitation of the current study is the absence of a live MPXV challenge animal model to directly confirm the protective efficacy of Tri(1–34). Due to the lack of an accessible Biosafety Level-3 (BSL-3) animal facility at our institution, such challenge studies could not be performed. Despite this limitation, the potent neutralizing activity demonstrated in PRNT assays and the robust Th1-biased cellular immune responses provide strong evidence for the potential protective capacity of the Tri(1–34) vaccine candidate. Compared to live-attenuated vaccines, the Tri(1–34) subunit vaccine offers a superior safety profile similar to a thermostable ionizable lipid nanoparticle platform using MPXV A29L mRNA vaccine candidate (Tian et al. 2024), as it lacks any infectious viral components and minimizes the risk of adverse effects like myocarditis or systemic rashes. Our study utilized Freund’s adjuvant to establish a proof-of-concept; however, for future clinical applications, evaluating Tri(1–34) with human-compatible adjuvants (e.g., Alum, MF59, or CpG) (Cheng et al. 2025; Li et al. 2024) will be a necessary next step. Additionally, further research into the cross-protection of Tri(1–34) against other emerging MPXV clades or orthopoxviruses would be highly valuable. In conclusion, the engineered Tri(1–34) antigen represents a potent, safe, and targeted subunit vaccine candidate. By focusing the immune response on the essential HBD of the A29L protein, we achieved high neutralizing antibody titers and a robust Th1 cellular response. This research provides a valuable framework for the development of next-generation Mpox vaccines that are more effective and safer than traditional live-attenuated options. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 1522 kb) Acknowledgements The authors are grateful to the excellent service provided by the Biosafety Level-3 Laboratory of National Taiwan University Hospital and the Biosafety Level-3 Laboratory of the First Core Laboratory, College of Medicine, National Taiwan University. We also thank the technical assistance from the Technology Commons, College of Life Science, National Taiwan University. Author contributions SYC and SCC designed and supervised the research. SYC and SCC acquired funds. CYL, TYC, PHC, TLC, and SYC performed experiments. CYL, TLC, SYC, and SCC analyzed data. SCC wrote the manuscript. All authors reviewed the final manuscript. Funding This work was supported by the National Science and Technology Council, Taiwan (grant numbers 111–2320-B-002–047, 113–2321-B-002–016, and 114–2740-B-002–003) and National Taiwan University (grant number 113L7226). Data availability No datasets were generated or analysed during the current study. Declarations Ethical statement The animals’ care and protocol have been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (approval number: NTU-112-EL-00192). Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Sui-Yuan Chang, Email: sychang@ntu.edu.tw. Shih-Chung Chang, Email: shihchung@ntu.edu.tw. References Associated Data Supplementary Materials Supplementary file1 (PDF 1522 kb) Data Availability Statement No datasets were generated or analysed during the current study.